#USA #New York #Securities Fraud #Pomerantz LLP #Protalix BioTherapeutics

Pomerantz Law Firm Investigates Protalix BioTherapeutics

In a significant development that has caught the attention of investors and analysts alike, Pomerantz LLP, a well-respected firm specializing in corporate litigation, has initiated an investigation concerning Protalix BioTherapeutics, Inc. (NYSE: PLX). The focus of this inquiry is to assess whether the company, along with its executives and board members, may have engaged in securities fraud or other unethical business practices that could have negatively impacted shareholders.

The timely announcement was made on October 28, 2025, as many investors are expressing concern over a recent downturn in Protalix's stock performance. This decline was primarily triggered by a disappointing announcement regarding the company’s product Elfabrio – pegunigalsidase alfa. On October 17, 2025, Protalix, in partnership with Chiesi Global Rare Diseases, disclosed that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) had issued a negative opinion regarding the proposed dosing regimen revision for Elfabrio. This regimen change was intended to enhance treatment options for patients, allowing for an infusion every four weeks instead of the previously approved regimen of every two weeks.

This announcement played a pivotal role in affecting investor sentiment, resulting in a sharp decline of $0.54 per share, translating to a staggering 22.5% drop, ultimately leaving the stock priced at $1.86 on that unfortunate day. Such a steep fall not only raised eyebrows but also prompted concerns over the management practices at Protalix, leading to the current investigation by Pomerantz LLP.

Pomerantz LLP has long been recognized as one of the premier law firms specializing in corporate securities and class-action litigation. Established over 85 years ago by the legendary Abraham L. Pomerantz, often referred to as the dean of class action litigation, the firm has been at the forefront of advocating for shareholders' rights and pursuing justice for victims of securities fraud. Their track record includes several successful class-action lawsuits that have generated multi-million dollar recoveries for class members. With their network of offices spread globally across major cities such as New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, Pomerantz maintains a significant presence in the legal landscape.

For investors who suspect that they have suffered losses due to Protalix's practices and the recent stock depreciation, Pomerantz LLP urges them to reach out to attorney Danielle Peyton via email at [email protected] or via phone at 646-581-9980, ext. 7980. The firm is keen on hearing from affected parties who may want to join in on the class-action proceedings.

The unfolding situation at Protalix serves as a critical reminder to investors about the necessity of vigilance and proper due diligence when investing in public companies. As news continues to develop, many are watching closely to see how Protalix and its executives will respond to these allegations and what potential repercussions may lie ahead in this ongoing inquiry. The commitment of Pomerantz LLP to uphold justice in the realm of financial investments stands unwavering, as they continue to advocate for the rights of shareholders.

In conclusion, the coming weeks will likely be pivotal for both Protalix BioTherapeutics and its investors as the investigation unfolds. Stakeholders and analysts alike will be keenly observing how these events may shape the future of the company and ultimately influence investor confidence moving forward.